even if it’s really at its early stages, I want to remind that the first CRISPR based therapies (for sickle cells disease and beta thalassemia) are already doing wonders and they are solving the problems with a single application, so we have some reasons to be hopeful.
The University of Ottawa is working on a potential breakthrough in treating complex diseases like cancer and cardiovascular disease using a combination of mRNA and RNAi therapies delivered via nanoparticles. This approach offers a multi-targeted strategy to address various challenges associated with these diseases, including tumor suppressor gene mutations, drug resistance, and tumor recurrence. By selectively enhancing or interfering with gene and protein expressions, the therapy aims to restore tumor suppressor gene expressions, enhance tumor antigens for immunotherapy, and target genes/proteins involved in drug resistance and cancer stem cell development. This novel method holds promise for improving therapeutic outcomes by synergistically promoting antitumoral factors while minimizing protumoral factors
New cancer treatment immuno therapy combined with guadecitabine in lung, breast, prostate bowel cancer makes cancer visible to immune sys